Stockscreener 앱 받기
20.66
1.92%
0.39
시간 외 거래:
20.66
전일 마감가:
$20.27
열려 있는:
$20.8
하루 거래량:
1.43M
Relative Volume:
2.16
시가총액:
$1.28B
수익:
-
순이익/손실:
$-209.84M
주가수익비율:
-4.5208
EPS:
-4.57
순현금흐름:
$-6.73M
1주 성능:
-8.54%
1개월 성능:
-32.53%
6개월 성능:
-17.52%
1년 성능:
+0.00%
1일 변동 폭
$19.80
$20.80
1주일 범위
$19.39
$23.43
52주 변동 폭
$16.50
$34.89
Damora Therapeutics Inc Stock (DMRA) Company Profile
명칭
Damora Therapeutics Inc
전화
(781) 281-9020
주소
221 CRESCENT STREET, WALTHAM
Compare DMRA vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
20.66 | 1.28B | 0 | -209.84M | -6.73M | -4.57 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 개시 | RBC Capital Mkts | Outperform |
| 2026-03-25 | 개시 | Evercore ISI | Outperform |
| 2026-02-17 | 개시 | UBS | Buy |
| 2026-01-07 | 개시 | Leerink Partners | Outperform |
| 2025-12-01 | 개시 | Guggenheim | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-11-23 | 개시 | BofA Securities | Buy |
| 2020-11-23 | 개시 | Credit Suisse | Outperform |
| 2020-11-23 | 개시 | SVB Leerink | Outperform |
모두보기
Damora Therapeutics Inc 주식(DMRA)의 최신 뉴스
DMRA Maintained by Guggenheim -- Price Target Raised to $60.00 - GuruFocus
Guggenheim maintains Buy rating on Damora Therapeutics, $60 price target - TradingView
Guggenheim raises Damora Therapeutics price target on MF sales outlook By Investing.com - Investing.com Canada
Damora Therapeutics: Potential Payday Is A Long Way Off (NASDAQ:DMRA) - Seeking Alpha
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Damora (DMRA) Update: Gains 1.68% to Reach $30.82 in the Current Update; Price Setup: the Near-Term Reference Band Stretches From $29.28 to $32.36 on the DayStrong Buy Stocks - vinanet.vn
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Damora (DMRA) Results at a Glance: The Available Earnings Metric Delivers a Miss in the Current Update; Session Move: The Share Price Sheds 6.23% in Latest TradingEarnings Decline Risk - vinanet.vn
DAMORA THERAPEUT (DMRA) Stock News, Mar 19-23, 2026 - Stock Titan
Damora Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Damora Therapeutics (DMRA) Is Up 5.1% After Starting CLARITY-101 mutCALR Trial Has The Bull Case Changed? - simplywall.st
Damora Therapeutics (DMRA) Starts CLARITY 101 Trial With Valuation Still In Focus - Sahm
Damora Therapeutics (DMRA) Adds 1.01% as Bulls Defend Key Support ZoneVolatility Smirk - vinanet.vn
Damora Therapeutics (DMRA) Advances 1.01% to $31.04 as Biotech Sentiment SteadiesKAMA Signal - dars.gov.et
Damora Therapeutics Director Andrew Cheng Granted Stock Options for 30,350 Shares - Kalkine Media
Damora Therapeutics (DMRA) director awarded 30,350 stock options at $31.00 strike - Stock Titan
Damora Therapeutics (DMRA) files Form 3 for new director Andrew Cheng - Stock Titan
DMRA Q1 2026 Earnings: EPS Misses Estimates by 56.8% as Shares Rise 8%Fiscal Year Earnings - vinanet.vn
Equities Analysts Offer Predictions for DMRA Q3 Earnings - MarketBeat
Damora Therapeutics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates The Upside - Seeking Alpha
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
DMRA SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus
Damora Therapeutics Q2 Results: Net Loss Widens To $31.2 Million - scanx.trade
Damora Therapeutics Q2 Results: EPS beats estimate, losses narrow - scanx.trade
Damora Therapeutics (NASDAQ: DMRA) resets $150M ATM after Cayman redomestication - Stock Titan
Damora Therapeutics, Inc. SEC Filing (Aug 10, 2026) - Stock Titan
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Damora Starts DMR-001 Trial With 100 mg Monthly Dose - Stock Titan
Damora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat
Does CLARITY-101’s mutCALR Antibody Launch Change The Bull Case For Damora Therapeutics (DMRA)? - simplywall.st
DMRA Q1 2026 Earnings: Wider-than-Expected Loss Signals Rising Clinical-Stage Cost PressuresPositive Surprise Momentum - dars.gov.et
Damara (DMRA): Lori Firmani plans sale of 1,800 common shares via Maxim - Stock Titan
Damora Therapeutics, Inc. Common Stock (DMRA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - marketbeat.com
Damora initiates phase 1 trial of mutCALR antibody therapy - Investing.com
Damora initiates phase 1 trial of mutCALR antibody therapy By Investing.com - Investing.com Australia
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis - The Manila Times
Damora Begins Testing Antibody Designed for Monthly Doses - Stock Titan
Damora Therapeutics earnings on deck as rare blood cancer race heats up - Investing.com India
Damora Therapeutics grants 451,000 stock options to six new hires - scanx.trade
DMRA Q1 2026 Earnings: EPS Misses by 56.8% as Loss Widens, Shares SlipROE Trend Analysis - careplusvn.com
Damora Therapeutics (DMRA) Edges Higher at $29.37 as Traders Eye Key Resistance at $30.84Fade Trade - dars.gov.et
Wedbush Increases Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Price Target to $40.00 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) to Post Earnings on Wednesday - MarketBeat
BlackRock (DMRA holder) reports 3.14M Damora Therapeutics shares in new ownership filing - Stock Titan
DMRA Initiates Coverage On Jefferies -- Rating Set to Buy, PT at $50 - GuruFocus
Jefferies Initiates Coverage on Damora Therapeutics With Buy Rating, $50 Price Target - marketscreener.com
Damora Therapeutics Inc (DMRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):